BRWA
RVNC

B. Riley Wealth Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

B. Riley Wealth Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,328
Closed -$288K – 1506
2021
Q3 		$288K Sell
10,328
-481
-4% -$13.7K 0.01% 1056
2021
Q2 		$321K Buy
10,809
+564
+6% +$16.3K 0.01% 990
2021
Q1 		$287K Buy
10,245
+600
+6% +$16.6K 0.01% 1026
2020
Q4 		$274K Hold
9,645
– – 0.01% 811
2020
Q3 		$243K Buy
9,645
+1,280
+15% +$33.6K 0.01% 782
2020
Q2 		$205K Buy
+8,365
New +$165K 0.01% 768

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

B. Riley Wealth Advisors's RVNC Position: Q4 2021 in Review

B. Riley Wealth Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 10,328 shares — an estimated $288K sold.

B. Riley Wealth Advisors first reported a position in RVNC in Q2 2020 and held it in 6 quarters. The position peaked at $321K in Q2 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • B. Riley Wealth Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 10,328 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $288K.
  • B. Riley Wealth Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
  • B. Riley Wealth Advisors's Revance Therapeutics, Inc. position peaked at $321K in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on B. Riley Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.